Cerity Partners LLC Invests $357,000 in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Key Points

• Cerity Partners LLC has made a new investment in BioNTech SE, purchasing 3,917 shares valued at approximately $357,000.
• Several hedge funds and institutional investors have either increased or initiated positions in BioNTech, indicating a growing interest in the company, with 15.52% of the stock now held by these entities.
• Analysts have varied opinions on BioNTech's stock, with consensus rating at "Moderate Buy" and a price target of $136.58, reflecting mixed future outlooks.

Cerity Partners LLC purchased a new stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 3,917 shares of the company's stock, valued at approximately $357,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its stake in BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after buying an additional 150 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of BioNTech during the fourth quarter valued at approximately $584,000. LPL Financial LLC increased its position in shares of BioNTech by 4.9% during the fourth quarter. LPL Financial LLC now owns 38,860 shares of the company's stock valued at $4,428,000 after acquiring an additional 1,800 shares during the last quarter. Allianz SE bought a new stake in BioNTech during the fourth quarter worth $90,000. Finally, Arrowstreet Capital Limited Partnership purchased a new position in BioNTech in the fourth quarter worth $3,513,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on BNTX shares. Truist Financial reaffirmed a "buy" rating and set a $155.00 target price (up from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. JPMorgan Chase & Co. reduced their price target on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research report on Thursday, May 22nd. Wall Street Zen raised shares of BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Morgan Stanley boosted their target price on shares of BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Finally, The Goldman Sachs Group started coverage on shares of BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 target price for the company. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $136.58.

BioNTech Trading Up 0.6%

NASDAQ:BNTX opened at $115.31 on Friday. BioNTech SE Sponsored ADR has a 1 year low of $76.53 and a 1 year high of $131.49. The stock's fifty day moving average price is $107.05 and its two-hundred day moving average price is $106.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.18 and a quick ratio of 10.02. The company has a market cap of $27.72 billion, a P/E ratio of -33.91 and a beta of 1.29.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.